Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> ABBVIE Latest News

JUN 29, 2015 - Benzinga

A Must Read - Share

Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent

Last Friday, Amgen, Inc. (NASDAQ: AMGN) filed an intellectual property rights (IPR) suit against AbbVie Inc (NYSE: ABBV)’s 8,916,157 patent, which claims an innovative formulation for Humira. Latest Ratings for ABBV DateFirmActionFromTo Jun 2015Piper JaffrayInitiates Coverage onOverweight Jun 2015JefferiesMaintainsBuy May 2015Morgan StanleyAssumesEqual-weight View More Analyst Ratings for ABBV View the Latest Analyst Ratings

Tags: Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent,  Abbvie Latest News

JUN 24, 2015 - Benzinga

A Must Read - Share

AbbVie Reports Phase 3B Results in Genotype 1b Chronic Hep C Patients with Compensated Liver Cirrhosis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis.1 Patients received 12 weeks of VIEKIRAX®

Tags: AbbVie Reports Phase 3B Results in Genotype 1b Chronic Hep C Patients with Compensated Liver Cirrhosis,  Abbvie Latest News

JUN 16, 2015 - Benzinga

A Must Read - Share

New Report: Abbvie Is Jefferies' Top Global Pharma Stock

Jefferies and analyst Jeffrey Holford recently released its monthly report on the global pharmaceuticals industry. The report includes Jefferies' top stock picks in the space, as well as a summary of key topics that investors should be watching. Latest Ratings for LLY DateFirmActionFromTo Apr 2015CitigroupUpgradesNeutralBuy Apr 2015BMO CapitalMaintainsMarket Perform Mar 2015SunTrust Robinson HumphreyMaintainsBuy View More Analyst Ratings for LLY View ...

Tags: New Report: Abbvie Is Jefferies' Top Global Pharma Stock,  Abbvie Latest News

JUN 15, 2015 - TheStreet

A Must Read - Share

AXON, REGN, BURL, FIVE: Jim Cramer's Views

NEW YORK (Real Money) -- Jim Cramer shares his views every day on RealMoney. Click here for a real-time look at his insights and musings. Biotech Moves Are Anything but Crazy Posted at 2:18 p.m. EDT on Thursday, June 11, 2015 It's not insanity. I am talking about these biotech moves we are seeing of late, including today's amazing run in the newly ...

Tags: AXON, REGN, BURL, FIVE: Jim Cramer's Views,  Abbvie Latest News